Trestle is pioneering the future of organ transplantation with its mission to transform the lives of patients suffering from kidney disease. By developing bioengineered kidneys, Trestle aims to address the critical shortage of donor organs and reduce the burden of dialysis. Our innovative approach combines cutting-edge biotechnology and human-machine interfaces to create functional, transplantable kidneys that integrate seamlessly with the human body. Trestle's advancements promise to enhance patient outcomes, improve quality of life, and redefine the possibilities in regenerative medicine.
Testimonial
Related Companies
Klona Biotech
The future of human tissue replacements using 3D printing
London, United Kingdom
Lyric Bio
Pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies
San Carlos, California
Eywa Biotech
Scaling the production of pharmaceutical-grade psychedelic compounds through synthetic biology
Montevideo, Uruguay · Buenos Aires, Argentina
PrettyLitter
Develops a lightweight cat litter that helps cat owners monitor their pets' health by changing colors in response to abnormalities in urine.
Los Angeles, United States
nVision
nVision’s focus is on women’s health. The company created the first FDA-cleared device for collecting cells from the fallopian tubes, which aimed to enable earlier diagnosis of ovarian cancer. In 2018, nVision was acquired by Boston Scientific.
Senodia
MEMS sensors for various applications.
China, Shanghai
Aanika
Innovative science-backed insurance solutions for agriculture and food industries with Bio technology.
Brooklyn, United States
